Malignant melanoma

22 trials 5 recruiting MedDRA PT
22 Registered trials
5 Recruiting
15 Unique sponsors
17 Unique IMPs
20 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
L Oncology (ATC L) 11
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Monoclonal antibody (immune) 5 substances
Checkpoint inhibitor (PD-1) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Alkylating agent 1 substance
Phase III: 3 Phase II: 8 Phase I/II: 1 Phase I: 6 Phase I (Other): 3 Phase I (First in Human): 1

Filter these 22 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 22 trials

Phase III

3 trials
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; FIANLIMAB; PEMBROLIZUMAB
    2022-501576-25-00 10 countries 2023 n=812
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; FIANLIMAB; PEMBROLIZUMAB
    2023-505772-30-00 12 countries 2022 n=562
    Ended

Phase II

8 trials
  • Genentech Inc. Commercial
    AUTOGENE CEVUMERAN; PEMBROLIZUMAB
    2023-507389-15-00 2 countries 2020 n=60
    Ended
  • Genmab A/S Commercial
    ACASUNLIMAB; PEMBROLIZUMAB
    2025-520468-16-00 4 countries n=129
    Ended
  • Immunocore Limited Commercial
    IPILIMUMAB; PEMBROLIZUMAB; TEBENTAFUSP
    2024-517290-24-00 5 countries 2017 n=96 Orphan
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Iovance Biotherapeutics Inc. Commercial
    ALDESLEUKIN; CYCLOPHOSPHAMIDE; LIFILEUCEL
    2025-522054-40-00 4 countries n=69
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; CEMIPLIMAB, FIANLIMAB; FIANLIMAB
    2022-502825-17-00 8 countries 2024 n=254
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM
    2024-512219-37-00 1 country 2022 n=35
    Recruiting

Phase I/II

1 trial
  • Glaxosmithkline Research & Development Limited Commercial
    COBOLIMAB; DOSTARLIMAB
    2024-511350-41-00 6 countries 2025 n=46
    Ended

Phase I

6 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
  • Microbiotica Limited Commercial
    IMP not specified
    2023-507377-17-00 3 countries 2024 n=27
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-513281-19-00 2 countries 2024 n=32
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-514745-10-00 5 countries 2025 n=58
    Ended

Phase I (Other)

3 trials
  • H e x a l AG Commercial
    IMP not specified
    2025-521919-39-00 4 countries 2026 n=83
    Recruiting
  • Incyte Corp. Commercial
    INCB099280; IPILIMUMAB
    2023-503243-34-00 3 countries n=23
    Ended
  • UZ Leuven Academic
    IMP not specified
    2023-510544-21-00 1 country 2025 n=4
    Recruiting

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 3 Phase I, Phase II, Phase III 0
Regeneron Pharmaceuticals Inc. Commercial 3 Phase II, Phase III 1
Immunocore Limited Commercial 2 Phase I, Phase II 1
Novartis Pharma AG Commercial 2 Phase I 0
Incyte Corp. Commercial 2 Phase I (Other), Phase II 0
Beigene Ltd. Commercial 1 Phase I 0
Microbiotica Limited Commercial 1 Phase I 0
H e x a l AG Commercial 1 Phase I (Other) 1
Genentech Inc. Commercial 1 Phase II 0
Genmab A/S Commercial 1 Phase II 0
Iovance Biotherapeutics Inc. Commercial 1 Phase II 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase I/II 0
UZ Leuven Academic 1 Phase I (Other) 1
Universitaetsklinikum Tuebingen AöR Academic 1 Phase II 1
New trials by year
2020
1
2021
1
2022
3
2023
3
2024
5
2025
4
2026
1
← All indication landscapes